Progress in medical management of intra-abdominal infection

Current Opinion in Infectious Diseases

Volumn 21, Issue 4, 2008, Pages 393-398

  Laterre, Pierre François ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Antibiotics; Intra abdominal infection; Management; Probiotics; Severe acute pancreatitis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; C REACTIVE PROTEIN; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; COLISTIN; DAPTOMYCIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PROBIOTIC AGENT; PROCALCITONIN; TIGECYCLINE; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ACUTE HEMORRHAGIC PANCREATITIS; ACUTE PANCREATITIS; ANTIBIOTIC THERAPY; CANDIDA; CASE MANAGEMENT; CONTINUOUS INFUSION; CRITICAL ILLNESS; DISEASE SEVERITY; DOSE CALCULATION; DRUG CHOICE; DRUG INDICATION; DRUG PENETRATION; HUMAN; INTENSIVE CARE; MORTALITY; MULTIDRUG RESISTANCE; PATIENT MONITORING; PROGNOSIS; REVIEW; THERAPY DELAY; TREATMENT DURATION; BACTERIAL INFECTION; CONVULSIVE THERAPY; INTRAVENOUS DRUG ADMINISTRATION; PANCREATITIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CONVULSIVE THERAPY; HUMANS; INFUSIONS, INTRAVENOUS; PANCREATITIS;

EID: 49049112293     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328306ef2a     Document Type: Review

References (30)

1. Solomkin JS, Dellinger EP, Christou NV, et al. Results of a multicenter trial comparing imipenem/cilastin to tobramycin/clindamycin in intra-abdominal infections. Ann Surg 1990; 212:581-591.
2. Falagas ME, Barefoot L, Griffith J, et al. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996; 15:913-921.
3. Montravers P, Gauzit R, Muller C, et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996; 23:486-494.
4. Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004; 23:682-687.
5. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect (Larchmt) 2002; 3:175-233.
6. Garbino J, Villiger P, Caviezel A, et al. A randomized prospective study of cefepime plus metronidazole with imipenem-cilastatin in the treatment of intra-abdominal infections. Infection 2007; 35:161-166.
7. Malangoni MA, Song J, Herrington J, et al. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006; 244:204-211.
8. Montravers P, Dupont H, Gauzit R, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006; 34:646-652.
9. Seguin P, Laviolle B, Chanavaz C, et al. Factors associated with multidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin Microbiol Infect 2006; 12:980-985.
10. Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008; 14 (S1):198-202.
11. Anthony KB, Fishman NO, Linkin DR, et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46:567-570.
12. Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect Dis 2005; 5:88.
13. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596.
14. Buijk SLCE, Gyssens IC, Mouton JW, et al. Pharmacokinetics of ceftazidime in serum and peritoneal exudates during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 2002; 49:121-128.
15. Ikawa K, Morikawa N, Hayato S, et al. Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients. Int J Antimicrob Agents 2007; 30:270-273.
16. Karjagin J, Lefeuvre S, Oselin K, et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther 2008; 83:452-459.
17. Stass H, Rink AD, Delesen H, et al. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58:693-696.
18. Hedrick TL, Evans HL, Smith RL, et al. Can we define the ideal duration of antibiotic therapy? Surg Infect (Larchmt) 2006; 7:419-432.
19. Basoli A, Chirletti P, Cirino E, et al. A prospective, double-blind, multicenter, randomized trial comparing ertapenem 3 vs >or=5 days in community-acquired intraabdominal infection. J Gastrointest Surg 2008; 12:592-600. Prospective RCT showing that a 3-day course of ertapenem achieved similar clinical and bacteriological cure rates compared with a prolonged treatment of at least 5 days in localized IAI requiring surgery.
20. Pederzoli P, Bassi C, Vesentini S, et al. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet 1993; 176:480-483.
21. Sainio V, Kemppainen E, Puolakkainen P, et al. Early antibiotic treatment in acute necrotising pancreatitis. Lancet 1995; 346:663-667.
22. Delcenserie R, Yzet T, Ducroix JP. Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis. Pancreas 1996; 13:198-201.
23. Isenmann R, Rünzi M, Kron M, et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. Gastroenterology 2004; 126:997-1004. First, large, double-blind study in patients with a predicted severe acute pancreatitis showing that early antibiotic prophylaxis did not reduce the incidence of pancreatic necrosis infection, the need for surgery, the ICU and hospital stays nor hospital mortality.
24. Dellinger EP, Tellado JM, Soto NE, et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study. Ann Surg 2007; 245:674-683. Second large multicenter, RCT comparing meropenem with placebo in severe necrotizing pancreatitis demonstrating that early antibiotic therapy did not reduce the incidence of pancreatic necrosis infection, requirement of surgery and mortality.
25. Nathens AB, Curtis JR, Beale RJ, et al. Management of the critically ill patient with severe acute pancreatitis. Crit Care Med 2004; 32:2524-2536.
26. Uhl W, Warshaw A, Imrie C, et al. IAP Guidelines for the Surgical Management of Acute Pancreatitis. Pancreatology 2002; 2:565-573.
27. Rau BM, Kemppainen EA, Gumbs AA, et al. Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis (PCT): a prospective international multicenter study. Ann Surg 2007; 245:745-754. Prospective multicenter study enrolling patients with severe pancreatitis suggesting that a PCT value of at least 3.5 mg/ml on 2 consecutive days had a high sensitivity and specificity compared with CRP to assess pancreatic necrosis infection in multiple organ dysfunction and nonsurvival.
28. Rayes N, Seehofer D, Theruvath T, et al. Supply of pre and probiotics reduces bacterial infection rates after liver transplantation: a randomized, double-blind trial. Am J Transplant 2005; 5:125-130.
29. Rayes N, Seehofer D, Theruvath T, et al. Effect of enteral nutrition and synbiotics on bacterial infection rates after pylorus-preserving pancreatoduodenectomy: a randomized, double-blind trial. Ann Surg 2007; 246:36-41.
30. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:651-659. A large well designed study showing that, contrary to previous suggestions, probiotics do not reduce the incidence of infections in severe acute pancreatitis and may be associated with increased mortality.